VS
Vijender Singh
About Vijender Singh
Data last updated:
Vijender Singh is a Director at Corpus Pharmaceuticals India Private Limited (since 2021), Director at Astroveda Applications Private Limited (since 2021) and Director at Corpus Retails Private Limited (since 2021). The companies operate in Healthcare, Information Technology and Service. The largest current company by reported revenue is Corpus Pharmaceuticals India Private Limited at ₹7 Lakh (FY 2020).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Corpus Pharmaceuticals India Private Limited U33100DL2018PTC339418 | Director | 29 Jun 2021 | 2018 | ₹7 Lakh (FY 2020) | Active |
| Astroveda Applications Private Limited U72900HR2021PTC097080 | Director | 18 Aug 2021 | 2021 | Active | |
| Corpus Retails Private Limited U93090DL2019PTC346193 | Director | 28 Jul 2021 | 2019 | Active |
Board colleagues of Vijender Singh
| Name | DIN | Company | Designation |
|---|---|---|---|
| Prashant | 08237579 | Corpus Pharmaceuticals India Private Limited , Astroveda Applications Private Limited and 1 more | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Vijender Singh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vijender Singh
Vijender Singh currently holds 3 directorships: Corpus Pharmaceuticals India Private Limited (Director, since 29 Jun 2021, revenue ₹7 Lakh (FY 2020)); Astroveda Applications Private Limited (Director, since 18 Aug 2021); Corpus Retails Private Limited (Director, since 28 Jul 2021).
Vijender Singh was first appointed on 29 Jun 2021 as Director at Corpus Pharmaceuticals India Private Limited.
The current boards of Vijender Singh's companies include Prashant (Corpus Pharmaceuticals India Private Limited).